Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DuPont Pharmaceuticals' Teti Adds CEO To Title With Landgraf Resignation

Executive Summary

DuPont President-Pharmaceuticals Nicholas Teti will add Chief Executive Officer to his title with the resignation of Kurt Landgraf, effective May 15.

You may also be interested in...



Pharmacia North America Rx President Is Spiers; Hassan Adds Chairman Title

Pharmacia North American Pharmaceuticals President Mark Spiers will lead the company's search for a new head of U.S. sales.

DuPont Spinning Off Rx Business As Cozaar Profit-Share Trigger Nears

DuPont's handling of the profit-sharing agreement for Cozaar is a central consideration in the valuing of the company's planned prescription drug spin-off.

DuPont Spinning Off Rx Business As Cozaar Profit-Share Trigger Nears

DuPont's handling of the profit-sharing agreement for Cozaar is a central consideration in the valuing of the company's planned prescription drug spin-off.

Related Content

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel